# Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia

> **NCT06516679** · PHASE2 · RECRUITING · sponsor: **Yonsei University** · enrollment: 40 (estimated)

## Conditions studied

- Leukemia, Lymphoid

## Interventions

- **DRUG:** Consolidation #4(without daunorubicin)
- **DRUG:** Consolidation #4(with daunorubicin)
- **DRUG:** Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)

## Key facts

- **NCT ID:** NCT06516679
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2032-08-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06516679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06516679, "Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06516679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*